Martin H. Voss, MD

Martin H. Voss, MD, medical oncologists, Memorial Sloan Kettering Cancer Center, reviews the method of design and results for the phase I/II study of the experimental antiPD-1 anitbody MEDI0680 plus durvalumab (Imfinzi) versus nivolumab (Opdivo) monotherapy in patients with metastatic clear cell renal cell carcinoma (ccRCC) (NCT02118337).

The study was a randomized, open-label study evaluating the safety, efficacy, and the anti-tumor activity of the MEDI0680/durvalumab combination. The research hypothesis behind the evaluation was that monotherapy alone would not have an effect on all of the interactions between the cells and continue to inhibit the tumor microenvironment. Combinations of PD-1 and PD-L1 agents, on the other hand, can block the interactions between cells.

Videos

Martin H. Voss, reviews the method of design and results for the phase I/II study of the experimental anti&ndash;PD-1 anitbody MEDI0680 plus durvalumab versus nivolumab monotherapy in patients with metastatic clear cell renal cell carcinoma.<br />
&nbsp;

Exploring MEDI0680/Durvalumab Versus Nivolumab in Metastatic ccRCC

Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.

One of the biggest concerns with neoadjuvant approaches compared with adjuvant treatments for nonmetastatic disease is whether neoadjuvant therapies will delay the timing of surgeries, according to Voss. Most of the drugs used in the neoadjuvant setting have proven to work well with subsequent surgery and have not postponed timing.

Addressing Concerns for Neoadjuvant Therapies in Locally Advanced Kidney Cancer

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the phase I/II DART study. The study compared

dalantercept plus axitinib with placebo plus axitinib for patients with advanced clear cell renal cell carcinoma

Dose-determining toxicities for dalantercept were fluid retention and anemia.

No additive toxicity was observed. The combination was well tolerated, even at the highest dose levels.

Median PFS was approximately 8 months for the entire study population.

Median PFS has not yet been reached among patients receiving the dose chosen for part II of the study.

Articles

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the phase I/II DART study.

Martin H. Voss, MD | Authors

Articles

Exploring MEDI0680/Durvalumab Versus Nivolumab in Metastatic ccRCC

Addressing Concerns for Neoadjuvant Therapies in Locally Advanced Kidney Cancer

Combining Dalantercept and Axitinib for Advanced Kidney Cancer